This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Quintero, I. B. Articles by Vihko, P. T. Search for Related Content PubMed PubMed Citation Articles by Quintero, I. B. Articles by Vihko, P. T.

Prostatic Acid Phosphatase Is Not a Prostate Specific Target

¹ Research Center for Molecular Endocrinology and WHO Collaborating Centre, Biocenter Oulu, University of Oulu; Departments of ² Surgery, Division of Urology, and ³ Pathology, Oulu University Hospital, Oulu, Finland; ⁴ Department of Biological and Environmental Sciences, Division of Biochemistry, and ⁵ Institute of Biotechnology, Electron Microscopy Unit, University of Helsinki, Helsinki, Finland

Requests for reprints: Pirkko T. Vihko, Department of Biological and Environmental Sciences, Division of Biochemistry, FI-00014 University of Helsinki, Helsinki, Finland. Phone: 358-40-543-1734; Fax: 358-9-1915-9694; E-mail: pirkko.vihko{at}helsinki.fi.

Prostatic acid phosphatase (PAP) is currently evaluated as a target for vaccine immunotherapy of prostate cancer. This is based on the previous knowledge about secretory PAP and its high prostatic expression. We describe a novel PAP spliced variant mRNA encoding a type I transmembrane (TM) protein with the extracellular NH₂-terminal phosphatase activity and the COOH-terminal lysosomal targeting signal (Yxx). TM-PAP is widely expressed in nonprostatic tissues like brain, kidney, liver, lung, muscle, placenta, salivary gland, spleen, thyroid, and thymus. TM-PAP is also expressed in fibroblast, Schwann, and LNCaP cells, but not in PC-3 cells. In well-differentiated human prostate cancer tissue specimens, the expression of secretory PAP, but not TM-PAP, is significantly decreased. TM-PAP is localized in the plasma membrane-endosomal-lysosomal pathway and is colocalized with the lipid raft marker flotillin-1. No cytosolic PAP is detected. We conclude that the wide expression of TM-PAP in, for instance, neuronal and muscle tissues must be taken into account in the design of PAP-based immunotherapy approaches. [Cancer Res 2007;67(14):6549–54]